Enhanced Place Finding (EPF) of TB transmission hotspots

Project Details


TB is transmitted via person-to-person aerosols. Recent studies suggests that in TB endemic areas up to 70% of
transmission events take place outside the household in public places. Moreover, TB transmission is unequally
spatially distributed and occurs in transmission hotspot areas. Mathematical models consequently demonstrated that
identifying hotspots and blocking within-hotspot-transmission through targeted public health interventions will be the
most efficient way of lowering the TB burden. In the present PoC proposal we aim to complement the populationbased
Enhanced-Case-Finding intervention tested in the INTERRUPTB study, with a spatially more targeted
“Enhanced-Place-Finding” (EPF) approach to identify transmission hotspots in an unbiased fashion. Using traditional
methods to find transmission hotspots can only be done retrospectively after years of data collection. Therefore
we propose a novel EPF strategy to detect transmission hotspots in real-time using phone-tracking technology to
establish a spatial map of aggregated TB patients movements.

Within the ERC-funded INTERRUPTB study in The
Gambia, we sequenced 2000 mycobacterial isolates, which allows us to establish a bacterial genetic transmission
network. Within the PoC proposal, we seek to reconsent these patients to analyze their everyday movements using
classical contact investigation complemented by phone tracking, to determine which public places have an increased
risk of TB transmission. We aim to demonstrate that phone tracking of TB patients can be a cheap, easy, and, most
importantly, prospective TB transmission hotspots identification tool, no longer requiring molecular epidemiological
investigations. Such a finding can ultimately be developed into an app that warns national TB programs of early TB
outbreaks, so that early public health measures like increased ventilation and active case finding can be initiated. This
approach can furthermore be applied to other infectious diseases.
Effective start/end date1/09/1731/12/19


  • European Commission: €149,783.00